Synthesis and characteristics of the fluorouracil-dextran conjugates

Pharmazie

Volumn 61, Issue 5, 2006, Pages 489-490

  Hao, Ai Jun ^a   Deng, Ying Jie ^a   Suo, Xu Bin ^a   Cao, Yan Hong ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Changli Traditional Chinese Medical Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; DEXTRAN; FLUOROURACIL;

ARTICLE; CATALYSIS; DRUG CONJUGATION; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SUBSTITUTION REACTION; ULTRAVIOLET SPECTROSCOPY;

ANTIMETABOLITES, ANTINEOPLASTIC; BUFFERS; DEXTRANS; DRUG CARRIERS; FLUOROURACIL; TEMPERATURE;

EID: 33646574620     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Bamford CH, Middleton IP, AI-Lamee KG (1986) Studies of the esterification of dextran: Routes to bioactive polymers and graft copolymers. Polymer 27: 1981-1985.
2. Chung SM, Yoon EJ, Kim SH, Lee MG, Lee H, Park MK, Kim CK (1991) Pharmacokinetics of 5-fluorouracil after intravenous infusion of 5-fluorouracil-acetic acid-human serum albumin conjugates to rabbits. Int J Pharm 68: 61-68.
3. Longley DB, Harkin DP, Johnston PG (2003) 5-Huorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
4. McLeod AD, Friend DR, Tozer TN (1993) Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery. Int J Pharm 92: 105-114.
5. Mehvar R (2000) Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Release 69: 1-25.
6. Nichifor M, Stanciu MC, Zhu XX (2004) Bile acids covalently bound to polysaccharides 2. Dextran with pendant cholic acid groups. React Funct Polym 59: 141-148.
7. Tada M (1975) Antineoplastic agents. The preparation of 5-fluorouracil-acetic acid derivative. Bull Chem Soc Jap 48:3427-3428.
8. Takakura Y, Hashida M (1995) Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit Rev Oncol Hematol 18: 207-231.